Most widely held works by
Schweizerische Nationalliga für Krebsbekämpfung und Krebsforschung

Aging and cancer by Frederick F Holmes(
Book
)2
editions published
in
1983
in
English
and held by
208 WorldCat member
libraries
worldwide
The life of a human being is finite, and all humans age (see Fries 1980). It is difficult to separate the effects of disease
on organs and tissues from those expected of aging. This is particularly true for vascular and degenerative processes, for
which there are no clear boundaries between aging and disease. Morbidity and mortality from heart disease and stroke are probably
due both to disease and to changes of aging. For cancer, the second leading cause of death in America, the situation is quite
different; cancer is clearly a disease and is not a change expected with aging. Cancer incidence increases almost logarithmically
after age 40. In the United States about one-half of all cases of cancer are diagnosed after age 65, although those over 65
comprise less than one-eighth of the population. Thus, cancer is very much a disease of the elderly. There are at least two
reasons for this: first, the prolonged exposure to cancer-inducing agents, and second, the waning power of immune defenses
against cancer

Investigation and stimulation of immunity in cancer patients by Georges Mathé(
Book
)6
editions published
in
1974
in
English
and held by
190 WorldCat member
libraries
worldwide
G. MATHE Institut de Cancerologie et d'Immunogenetique (INSERM et Association Claude-Bernad), H6pital Paul-Brousse and Institute
Gustave-Roussy, Villejuif 20 years ago, the main, if not only object of the cancer therapist was to effect complete surgical
exeresis or radiotherapeutic destruction of a local tumor, or to obtain, by means of chemotherapy, an "apparently complete
regression" of a local or disseminated neoplasia. Today it is realized that (a) at the time of the operation or radiotherapy,
two patients in every three carrying an apparently localized tumor have a few cancer cells outside the area where the tumor
seems localized; (b) when "apparently complete regression" or even an "apparently complete remission" is induced by chemotherapy,
not all the neoplastic cells have been eradicated. In both cases an imperceptible residual neoplasm persists, the growth of
which will in due course make it perceptible again, giving rise to metastasis or to a systemic or localized relapse. There
is thus an urgent need for a new technique capable of killing the last cell or cells. Our experiments in mice on the effectiveness
of active immunotherapy, which involves the manipulation of the immune machinery, have shown that this treatment is able to
kill all the cells, down to the very last cell of a given leukemia, provided that the total number of cells does not exceed
a few thousand [1, 2]

Antitumor antibiotics by Stephen K Carter(
Book
)3
editions published
in
1978
in
English
and held by
188 WorldCat member
libraries
worldwide
The scientific collaboration between the United States and Japan in the field of cancer goes back many years. In this successful
international collaboration cancer chemotherapy has been one of the most productive areas. Pioneers such as YOSHIDA, UMEZAWA,
SHEAR, and GOLDIN established firm links of mutual trust and respect in the period after the Second Great War. Japanese drugs,
such as mitomycin C and bleomycin have become mainstays of clinical oncology in the U.S. and throughout the world. Many drugs
developed in the U.S. have become established in Japanese cancer therapy. Within the cancer chemotherapy field the antitumor
antibiotics rank as one of the most important groups. In the U . S.-J apanese collaboration this group of drugs has taken
the paramount role. The Japanese, under the leadership of U mezawa, are considered to be among the most innovative and productive
in this area which has also had great emphasis in the United States as part of the National Cancer Institute's drug development
program and in the pharmaceutical industry. This extended collaboration in general oncology, and chemotherapy in particular,
has received increased impetus by and support from the official U . S.-J apan Joint Agreement on cancer research, which was
established in 1974 between the National Cancer Institute and the Japanese Society for the Promotion of Science. One of the
subsections of this agreement is cancer therapy with emphasis on chemotherapy

Lymphocytes, macrophages, and cancer by Georges Mathé(
Book
)2
editions published
in
1976
in
English
and held by
187 WorldCat member
libraries
worldwide
Fresh living Bacillus Calmette-Guerin (BeG), injected i.v. into (C57BI/ 6xDBA/2)FI mice, activated peritoneal macrophages
rendering them highly cytotoxic for tumor cells in vitro. This cytotoxic activity w~s already maximal 14 days after injection
of 1 mg of BCG and remained stable when 3 or 5 mg of BCG were given. At the same time spleen cells of the BCG-treat~d mice
showed strongly depressed responses to the T-cell mitogens, PHA and Con A, irrespective of the dose of BCG injected. The inhibitory
effect was shown to be mediated by suppressor cells which had characteristics of macrophages since they could be removed by
carbonyl iron and magnet treatment and were adherent to plastic. In contrast to it was observed after injec tion of 1 mg of
BCG, these suppressor cells alone did not account for the depression of T-cell re.sponses induced by higher doses of BCG.
Nylon-nonadherent cell populations obtained from spleen cells treated with 3 or 5 mg BCG partially retained the inhibitory
activity suggesting that suppressor T cells were also induced after injection of high doses of BCG. In contrast, the responses
to the B-cell mitogen LPS of unfractionated and macrophage-depleted spleen cells were not affected or significantly enhanced
depending on the dose of BCG injected

Lung cancer by William Duncan(
Book
)3
editions published
in
1984
in
English
and held by
187 WorldCat member
libraries
worldwide
Each year a multidisciplinary symposium on Clinical Oncology is organised by the Royal College of Radiologists in London.
The fifth symposium was held in February 1983 when the subject was Lung Cancer. The clinical and social importance of lung
cancer cannot be too greatly stated. The disease is an enormous cause of morbidity and remains the most common cause of death
from cancer in males in the Western World. Sadly, the incidence of the disease continues to increase in women in the United
Kingdom, and the success of commercial pressure to encourage cigarette smoking in the developing countries must mean that
an increasing community health problem may be anticipated. The methods used to promote cigarette smoking are dramatically
described in this publication. The enormous weight of vested interest in tobacco consumption makes education of the public
and of politi cians about the health hazards of smoking a formidable battle waged with very limited resources. Attitudes can
be changed by skilled professional groups, but they do require much greater international support. The prognosis of patients
with lung cancer remains extremely poor. Optimum management requires expert pretreatment assessment and careful selection
of the many forms of treatment available. The techniques of clinical assessment and staging, radiological investiga- Preface
VI tion, and pathological classification are all described in some detail and their limitations are well illustrated. It is
hoped that meetings of this kind will stimulate the further collaboration of multidisciplinary groups to improve our understanding
of these aggressive diseases

Clinical interest of steroid hormone receptors in breast cancer by G Leclercq(
Book
)3
editions published
in
1984
in
English
and held by
184 WorldCat member
libraries
worldwide
Several papers dealing with the clinical relevance of steroid hormone receptors in breast cancer have already been published.
However, no publication has overviewed studies currently being conducted in Europe, nor is there a register of the european
centers performing receptor assays. It has been our purpose to fill these gaps. A large majority of authors who we contacted
kindly agreed to con tribute to our book. Papers were grouped into six main parts according to their contents. The abundance
of clinical data relevant to receptor assays led us to add critical summaries to help the reader to form his own opinions
on the subject. We would like to thank Drs. R.J.B. King, G. Contesso, L. Santi, and E. Engelsman, who helped us in this regard.
We hope that this book will enable the reader to become acquainted with the present state of European steroid hormone receptor
studies devoted to breast cancer treatment. We also hope that it will promote cooperation between European oncologists involved
in this field of research

New drugs in cancer chemotherapy by Stephen K Carter(
Book
)3
editions published
in
1981
in
English
and held by
181 WorldCat member
libraries
worldwide
The Analog Potential in Cancer Chemotherapy in the United States and Japan S.K. Carter Northern California Cancer Program,
1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research
between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the
National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science.
Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development
in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This
has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered
and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure
provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that
the therapeutic index of active structures can be improved so as to achieve superior clinical results

New anticancer drugs by Stephen K Carter(
Book
)4
editions published
between
1979
and
1980
in
English
and held by
179 WorldCat member
libraries
worldwide

Complications of cancer chemotherapy by Georges Mathé(
Book
)4
editions published
in
1974
in
English
and held by
179 WorldCat member
libraries
worldwide
G. MATHE and R.K. OLDHAM'~ Institut de Cancerologie et d'Immunogem!tique, Hopital Paul Brousse, Villejuif Since the last war,
cancer chemotherapy has been the object of very intensive and expensive research. Nevertheless, its development has been very
slow, and its ultimate potential is today somewhat in doubt. In doubt because it does not cure any cancer patients except
a) females carrying placental choriocarcinoma, a semi-allogenic tumor, in which case, cure may be in fluenced by immune rejection,
and b) children suffering from Burkitt's tumor, where the probable reason for the cure is that all the neoplastic cells are
in the cycle, which is a unique condition among all the human tumor varieties. Whether the long term survivors in acute leukemia,
lymphomas, certain sarcomas and certain testicular tumors are "cures" will require longer follow-up. The idea that chemotherapy
does not cure most cancer patients because all their neoplastic cells are not in cycle has led to the use of drug combinations.
Whatever they are, "cocktail combinations" which are made up of drugs given according to any timing, or scientific combinations,
based on pharmacodynamics, pharmaco kinetics or cell kinetics data, are more toxic than single drugs, and are all the more
toxic as the number of drugs in the combination is increased

Lymphoid neoplasias by Georges Mathé(
Book
)10
editions published
in
1978
in
English
and held by
177 WorldCat member
libraries
worldwide
We have studied 24 cases of secondarily leukemic (stage V) lymphosarcoma (LS), 31 cases of "d'emblee" leukemic LS, and ten
cases of lymphoid leukemic neoplasias transitional between "d'emblee" leukemic LS and chronic lymphocytic leukemia (eLL).
These cases only concern the common types ofthe WHO classification ofLS, i.e., the prolymphocytic, the lymphoblastic, and
the immunoblastic. Some cases have also been classified by cell surface markers. The secondarily leukemic conversion occurred
in 40% of the lymphoblastic types, in 14% of the prolymphocytic types, and in 17% of the immunoblastic types. It never occurred
at stage I but could occur after any other stage. The mediastinal involvement was observed in three types, but most often
in the lymphoblastic type. The prognosis after an acute lymphoid leukemia (ALL) treatment comprising active immunotherapy
following chemo(radio)therapy is better for the leukemic prolymphocytic and lymphoblastic LS than for the immunoblastic type.
Two patients (one of the lymphoblastic type) are in complete remission after 8 and 5 years, respectively. We have described
ten cases of "d'emblee" leukemic LS with either large lymphoid or extra lymphoid masses, bone marrow leukemic cell involvement,
and LS aspects of neoplastic cells. Mediastinal, abdominal, or other tumor masses are frequent

Hairy-cell leukaemia by J. C Cawley(
Book
)2
editions published
in
1980
in
English
and held by
177 WorldCat member
libraries
worldwide
Hairy-cell leukaemia (HCL) is an established clinicopathological entity typified by a chronic picture of substantial splenomegaly,
less frequent hepatomegaly, and only inconspicuous lymphadenopathy. Central to the diagnosis is the pathognomonic hairy cell
(HC), a dis tinctive mononuclear cell that circulates in varying numbers and infiltrates a variety of organs, including the
bone marrow and spleen. Peripheral pancytopenia is often present, and circulating HCs may be infrequent. HCs are invariably
present in the bone marrow; but, per haps because of the extensive fibrosis characteristic of the disease, the marrow is frequently
difficult to aspirate, and confirmation of the diagnosis may require histopathological ex amination of biopsy material. The
incidence of the disease has been given as 2% ofleukaemias [29, 319] or as approximately 1 % of identifiable lymphomas [230].
Our own experience of collecting cases in the United Kingdom leads us to expect that at any given time one patient with HCL
will be attending a clinic serving some 150,000 people

Endocrine treatment of breast cancer : a new approach by B Henningsen(
Book
)3
editions published
in
1980
in
English
and held by
174 WorldCat member
libraries
worldwide
Progress in basic research has made it necessary to redetermine the possibility of classic endocrine therapy for the treatment
of patients with breast cancer. Exemplary, close cooperation between biochemis try and animal and clinical research led to
a truly interdisciplinary and international exchange of ideas and experience at a symposium held in autumn 1978 in Heidelberg.
We owe our thanks to ICI-Pharma for the kind support of this sym posIUm. The participation of Charles Huggins in the meeting
as honorary chairman signified to all participants the meaning of this joint endeavour. It was the same Charles Huggins who
through experimental work laid the foundation stone for endocrine ther apy of prostate and breast cancer, and who applied
his findings clinically. Thousands of patients owe to him relief from their suffering. He contributed greatly to the attempt
to find and stabilize the endocrine therapy for breast cancer, for which we thank him sincerely. We hope that the following
contributions will similarly serve the well-being of our patients

Malignant transformation by viruses by W. H Kirsten(
Book
)4
editions published
in
1966
in
English
and held by
174 WorldCat member
libraries
worldwide
The position of "Cancer Teaching Coordinator" at The University of Chicago has been a consistently rewarding one because of
the enthusiasm and support of the faculty and the students. This volume is the result of the second of two recent intensive
teach ing sessions which have been planned and implemented by the group which forms the Cancer Coordinator's Advisory Committee.
The first of these teaching sessions was held in early March of 1964 and was entitled "LEUKEMIA, A Current and Forward Look."
It attracted overflow attendance from the students and staff of this medical institution augmented by members of the other
medical centers in Chicago. It was a stimulating and instructive colloquium, and the only regret we heard expressed afterward
was that we had not arranged for publication of the many excellent presentations. One of the events commemorating the seventy-fifth
anniversary of the founding of The University of Chicago was this symposium on malignant transformations. This time the Committee
advised us to plan on speedy publication, and, logically, it chose Dr. Werner Kirsten, a member of our faculty and an active
and effective investigator in this general field of endeavor, to serve as editor of the volume. Again, two of the same ingredients
for effective instruction were blended: an excellent group of scientists presenting their latest work and a fine, attentive
audience of students and staff

Adjuvant chemotherapy of breast cancer by Hansjörg Senn(
Book
)2
editions published
in
1984
in
English
and held by
172 WorldCat member
libraries
worldwide
H.-J. Senn Adjuvant Chemotherapy (ACT) of breast cancer has now emerged as one of the controversial su):>jects in clinical
and also experimental oncology. Driven by growing frustration about stagnating cure rates in breast cancer [1,4] and stimulated
by elegant demonstration of highly curative effects of adjuvant systemic therapy in animal models [6, 11] and in several childhood
neoplasias [15], researchers introduced ACT to the primary treatment of breast cancer with great hope some 15 years ago. After
a first wave of isolated "historic" trials with generally limited but in one case remarkable success [5, 9], a second generation
of ACT studies was initiated by NSABP investigators and oncology centers in Europe [2, 6, 13]. These trials were well conducted
statistically and diagnostically, and all in the early 1970s included a surgical control arm. Early and intermediate beneficial
effects on relapse-free survival (RFS) after 2-3 years median observation time then prompted a whole series of ACT studies
in breast cancer. These "third-gener ation" studies usually regarded some positive influence of ACT as a given fact, dropping
surgical control regimens and comparing different ACT regimens, hopefully in a prospective, randomized way 1984 Fig. 1. The
mushrooming of adjuvant studies in breast cancer XII Introduction [reviews in 3, 14]. The "mushrooming" of ACT studies in
breast cancer during the last 10 and especially 5 years is demonstrated in Fig. 1, and it gets really cumbersome even for
the insider to keep on top of the multitude of sometimes conflicting data

Tactics and strategy in cancer treatment by European Organization for Research on Treatment of Cancer(
Book
)4
editions published
in
1977
in
English
and held by
168 WorldCat member
libraries
worldwide

Breast cancer, a challenging problem by M. L Griem(
Book
)7
editions published
in
1973
in
English
and held by
163 WorldCat member
libraries
worldwide
This volume summarizes the proceedings of the fifth biennial Cancer Teaching Symposium held on March 4 and 5, 1972 at the
University of Chicago Pritzker School of Medicine. The program was prepared by Drs. MELVIN GRIEM, ELWOOD JENSEN, HAROLD SUTTON,
JOHN ULTMANN, and ROBERT WISSLER. The purpose of the symposium was to present the current status of the challenging cancer
problem, breast carcinoma, to the staff and students of this medical center and to students and in terested physicians from
other institutions in the Chicago area. In a fashion similar to the other teaching symposia held in 1964, 1966, 1968,. and
1970, this symposium attracted over 450 physicians and scientists. In the course of one and one half days the audience had
the opportunity to listen to 18 invited speakers and to the lively discussions. The formal presentations are recorded in these
pages. This teaching symposium could not have been undertaken without the faithful assistance of the program committee, the
cancer training grant education committee, the staff who recorded and transcribed the proceedings, and the editorial assistants.
We wish to thank the following for their efforts: JULIE KANT, Administrative Secre tary for the Clinical Cancer Training Grant,
as well as Dr. JAMES MARKS, MARGARET WOEHRLE, FRIEDA RANNEY, and ROSIE BARTLETT. This symposium received financial support
from USPHS Clinical Cancer Train ing Grant 5T12 CA-08077-06 and from the Chicago Tumor Institute. MELVIN L. GRIEM, M.D. ROBERT
W. WISSLER, Ph. D., M.D

Scientific basis of cancer chemotherapy by Georges Mathé(
Book
)5
editions published
in
1969
in
English
and held by
146 WorldCat member
libraries
worldwide
Scientific Basis of Cancer Chemotherapy focuses on methods and approaches in the treatment of cancer, including detection,
chemotherapeutic agents, and hormonal therapy. The selection first offers information on the detection of anti-cancer agents
through screening tests and extracellular factors affecting the response of tumors to chemotherapeutic agents. Discussions
focus on induced and transplanted tumors, alkylating agents, anti-folics, rate of excretion, dosage regimen, and extra-cellular
deactivation. The text then elaborates on intracellular factors influencing the response of tumors t

Aseptic environments and cancer treatment by Georges Mathé(
Book
)4
editions published
in
1970
in
English
and held by
132 WorldCat member
libraries
worldwide
The 1969 Proceedings of the Plenary Session of the European Organization for Research on Treatment of Cancer have been divided
between two volumes of a com pletely different nature. Volume 29, Aseptic Environments and Cancer Treatment, deals not only
with the treatment of all types of cancer but also with aplastic treatment of bone marrow and certain other pathological conditions,
such as immunological insufficiency, bums etc. Hence the volume will be of interest not only to carcinologists and haematologists
but also to paediatricians, surgical units, intensive-care units, hospital administrators and architects and engineers who
specialize in hospital design and equipment. Volume 30, Advances in the Treatment of Acute (Blastic) Leukemias, deals with
a particular form of cancer and will have a more restricted readership of carcinologists specializing in leukemia and all
haematologists. Paris, April 1970 GEORGES MATHE Contents Introduction. G. MATHE. 1 Five Years Experience of the Clinical Use
of a Pathogen-Free Isolation Unit. G. MATHE, M. SCHNEIDER, 1. SCHWARZENBERG, J. 1. AMIEL, A. CATTAN, J.R. SCHLUMBERGER, M.
HAYAT, F. DE VASSAL, CL. JASMIN, and CL. ROSEN- FELD. With 3 Figures . 3 Protected Environments and the Use of Antibiotics.
H.E.M. KAY, J. BYRNE, B. JAMESON, and J. LYNCH . 14 Protected Environment, Prophylactic Antibiotics and Cancer Chemotherapy